Showing results (1-10 of 73) with videos related to
Sort By:
Pageof 8
The New Zealand Medical Journal|December 7, 2011
Access to new medicines in New Zealand compared to AustraliaMichael Wonder, Richard MilneExpert Review of Pharmacoeconomics & Outcomes Research|May 14, 2014
What can be gained from increased early-stage interaction between regulators, payers and the pharmaceutical industry?Michael WonderAustralian Health Review : a Publication of the Australian Hospital Association|March 10, 2015
Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New ZealandColman Taylor, Michael WonderInternational Journal of Technology Assessment in Health Care|June 12, 2020
Analysis of PBAC submissions and outcomes for medicines (2010-2018)Sean Lybrand, Michael WonderExpert Review of Pharmacoeconomics & Outcomes Research|May 5, 2015
What impact does 'conventional' economic evaluation have on patient access to new orphan medicines? A comparative study of their reimbursement in Australia (2005-2012)Michael Wonder, Geoffrey ChinValue in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 21, 2015
Assessment of the Quality of the Clinical Evidence in Submissions to the Australian Pharmaceutical Benefits Advisory Committee: Fit for Purpose?Michael Wonder, Sheryl DunlopThe New Zealand Medical Journal|August 19, 2016
Subsidised access to new melanoma drugs: in need of further innovation?Michael Wonder, Rosalie FisherSocial Studies of Science|August 2, 2012
Pharmaceutical prospects: biopharming and the geography of technological expectationsRichard MilneNew Genetics and Society|April 8, 2020
The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug developmentRichard MilneAustralian Health Review : a Publication of the Australian Hospital Association|May 11, 2019
Analysis of sponsor hearings on health technology assessment decision makingMelinda Flowers, Sean Lybrand, Michael WonderPageof 8